While working on a postgraduate research project on Pharmacovigilance through a grant from The University of Ferrara Italy and utilizing resources available at Queens University in New York, our founder Eric became increasingly aware that besides the safety concern of the drugs marketed in most developing countries and even some developed nations, access and cost were major issues to address.

The average life expectancy in most developing countries is 63 years mainly due to infant mortality and lack of management of chronic diseases like hypertension, diabetes and many others. On frequent trips to Africa and other developing countries during the project, he realized that most drugs commonly used to manage these chronic conditions were either unavailable, substandard or very costly and unaffordable due to inefficiency in supply chain, lack of inventory management or unscrupulous middle men price hikes.